Patients with tumor NeuGcGM3+/EGFR+ had a significantly poorer OS than those with NeuGcGM3+/EGFR− phenotype (40.0% versus 68.2%; p < 0.000; Fisher's exact test) (Figure 4(b)). Here, EGFR is linked to neoplasm.